Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sanofi-Aventis Sa (SNY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 125,485,664
  • Shares Outstanding, K 2,543,800
  • Annual Sales, $ 38,408 M
  • Annual Income, $ 4,864 M
  • 36-Month Beta 0.93
  • Price/Sales 3.37
  • Price/Cash Flow 10.75
  • Price/Book 1.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.97 +5.05%
on 06/15/17
50.18 -1.67%
on 06/02/17
+0.34 (+0.69%)
since 05/26/17
3-Month
43.97 +12.21%
on 04/21/17
50.24 -1.79%
on 05/16/17
+3.96 (+8.73%)
since 03/27/17
52-Week
36.81 +34.04%
on 10/26/16
50.24 -1.79%
on 05/16/17
+10.21 (+26.09%)
since 06/27/16

Most Recent Stories

More News
American Academy of Family Physicians Foundation Launches Highlight on VACCINATIONS 4 TEENS to Help Address Teen Under-Vaccination

The American Academy of Family Physicians Foundation today announced the launch of Highlight on VACCINATIONS 4 TEENS, a new program that will help family physicians educate teen patients and their families...

SAN : 6.62 (+0.91%)
SNY : 49.33 (-0.52%)
Sanofi Announces Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

Marketing authorisation for sarilumab offers a new treatment option for people in

SNY : 49.33 (-0.52%)
Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union

GUILDFORD, England, June 27, 2017 /PRNewswire/ --

SNY : 49.33 (-0.52%)
Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has granted marketing authorization for Kevzara® (sarilumab) in combination with methotrexate...

SAN : 6.62 (+0.91%)
REGN : 516.00 (+0.02%)
SNY : 49.33 (-0.52%)
Regeneron (REGN) Stock on Fire: What's Behind the Surge?

Shares of Regeneron Pharmaceuticals, Inc. (REGN) have moved up 14.8% over the last 30 days.

VVUS : 1.18 (-0.84%)
NVS : 85.96 (+0.24%)
REGN : 516.00 (+0.02%)
SNY : 49.33 (-0.52%)
Why You Should Add Novo Nordisk Stock to Your Portfolio

Novo Nordisk (NVO) is healthcare company and a with leadership in the global diabetes market. It looks like a great stock to buy now.

NVO : 43.89 (-1.13%)
MRK : 65.86 (-0.09%)
LLY : 83.77 (-0.61%)
SNY : 49.33 (-0.52%)
Shire (SHPG) Receives MAA Validation for Veyvondi by EMA

Shire plc (SHPG) announced that the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for Veyvondi to prevent and treat bleeding episodes and peri-operative bleeding...

VVUS : 1.18 (-0.84%)
SHPG : 173.87 (+0.28%)
MEIP : 2.33 (-0.49%)
SNY : 49.33 (-0.52%)
Seattle Genetics (SGEN) Submits BLA to FDA for Cancer Drug

Seattle Genetics, Inc. (SGEN) announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA for Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma...

VVUS : 1.18 (-0.84%)
SGEN : 55.02 (-2.71%)
MEIP : 2.33 (-0.49%)
SNY : 49.33 (-0.52%)
Horizon Pharma Gets Health Canada Approval for Procysbi

Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2...

VVUS : 1.18 (-0.84%)
HZNP : 11.97 (-0.42%)
MEIP : 2.33 (-0.49%)
SNY : 49.33 (-0.52%)
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio

The Zacks-categorized Large Cap Pharmaceuticals industry is among the top 21% of the 256 Zacks-ranked industries -- here is a look at 4 top-ranked stocks from this sector.

BAYRY : 137.3900 (+0.50%)
AZN : 34.75 (-1.14%)
HLUYY : 55.9700 (-0.37%)
SNY : 49.33 (-0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing...

See More

Support & Resistance

2nd Resistance Point 49.98
1st Resistance Point 49.79
Last Price 49.33
1st Support Level 49.48
2nd Support Level 49.36

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.